The regulatory approval paves the way for ChestEye deployments in the Brazilian market.

VILNIUS, LITHUANIA, February 15, 2023 /EINPresswire.com/ -- ChestEye application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency’s approval is one of Oxipit steps to increase global reach for company products.

“With many future-focused healthcare organizations, LatAm market shows tremendous potential for healthcare AI applications. Oxipit products have already shown strong market traction in the region. The ANVISA certification will solidify our presence in the Brazilian market, with new clinical deployments coming soon” - says Oxipit CEO Gediminas Peksys.

Oxipit ChestEye AI suite includes CAD, triage and quality assurance features. The product produces preliminary reports for 75 most common chest findings. The software can prioritize patient reporting workflow. The application can also act as a second reader - utilizing AI to look for findings that the radiologist might have missed in his report. Furthermore, ChestEye may be used for healthy patient report automation.

“ChestEye serves as the stepping stone for organizations to embrace AI. Starting from CAD and preliminary reports, healthcare institutions can then move to extended platform features - such as quality assurance or automation - based on their usage scenarios“ - adds Gediminas Peksys.

ANVISA certification is one of Oxipit steps towards expansion into new markets. The company recently closed a $4.9M funding round with the aim to boost global Oxipit presence.

The company is gearing up towards the European Congress of Radiology in March, where the updated Oxipit Quality AI powered double reading application will be presented to the European audience for the first time. At ECR Oxipit will also showcase ChestLink autonomous AI application, presenting possible autonomous reporting workflows and feedback from initial product deployments.

At ECR Oxipit AI medical imaging products will be presented at booth AI-38.

Mantas Miksys
Oxipit
email us here
Visit us on social media:
LinkedIn
Facebook
Twitter

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.